Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK

Nonalcoholic steatohepatitis (NASH) is recognized by hepatic lipid accumulation, inflammation, and fibrosis. No studies have evaluated the prolonged‐release pirfenidone (PR‐PFD) properties on NASH features. The aim of this study is to evaluate how PR‐PFD performs on metabolic functions, and provide...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hepatol Commun
Autores principales: Sandoval‐Rodriguez, Ana, Monroy‐Ramirez, Hugo Christian, Meza‐Rios, Alejandra, Garcia‐Bañuelos, Jesus, Vera‐Cruz, Jose, Gutiérrez‐Cuevas, Jorge, Silva‐Gomez, Jorge, Staels, Bart, Dominguez‐Rosales, Jose, Galicia‐Moreno, Marina, Vazquez‐Del Mercado, Monica, Navarro‐Partida, Jose, Santos‐Garcia, Arturo, Armendariz‐Borunda, Juan
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049672/
https://ncbi.nlm.nih.gov/pubmed/32140659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1474
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares